Rituximab Therapy for Treatment of Pemphigus in Southeast Asians

References

• DidonaD, MaglieR, EmingR, HertlM. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418.31293582
   PubMed Web of Science ®Google Scholar
• KasperkiewiczM, EllebrechtCT, TakahashiH, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.28492232
   PubMed Web of Science ®Google Scholar
• KridinK, SagiSZ, BergmanR. Mortality and cause of death in patients with pemphigus. Acta Derm Venereol. 2017;97(5):607–611. doi:10.2340/00015555-261128093595
   PubMed Web of Science ®Google Scholar
• PollmannR, SchmidtT, EmingR, HertlM. Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clin Rev Allergy Immunol. 2018;54(1):1–25.29313220
   PubMed Web of Science ®Google Scholar
• HammersCM, StanleyJR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016;11(1):175–197. doi:10.1146/annurev-pathol-012615-04431326907530
   PubMed Web of Science ®Google Scholar
• BystrynJC. Adjuvant therapy of pemphigus. Arch Dermatol. 1984;120(7):941–951. doi:10.1001/archderm.1984.016504301270246375579
   PubMedGoogle Scholar
• BystrynJC, SteinmanNM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132(2):203–212. doi:10.1001/archderm.1996.038902601050168629830
   PubMedGoogle Scholar
• RiceJB, WhiteAG, ScarpatiLM, WanG, NelsonWW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216–2229. doi:10.1016/j.clinthera.2017.09.01129055500
   PubMed Web of Science ®Google Scholar
• HarmanKE, BrownD, ExtonLS, et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177(5):1170–1201. doi:10.1111/bjd.1593029192996
   PubMed Web of Science ®Google Scholar
• TranKD, WolvertonJE, SoterNA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013;169(4):916–921. doi:10.1111/bjd.1247423772610
   PubMed Web of Science ®Google Scholar
• SukanjanapongS, ThongtanD, KanokrungseeS, SuchonwanitP, ChanprapaphK. A comparison of azathioprine and mycophenolate mofetil as adjuvant drugs in patients with pemphigus: a Retrospective Cohort Study. Dermatol Ther (Heidelb). 2020;10(1):179–189. doi:10.1007/s13555-019-00346-x31865535
   PubMed Web of Science ®Google Scholar
• SardanaK, AgarwalP, BansalS, UppalB, GargVK. A comparative effectiveness research of azathioprine and cyclophosphamide on the clinical and serological response in pemphigus vulgaris. Indian J Dermatol. 2016;61(4):418–426. doi:10.4103/0019-5154.18571027512188
   PubMed Web of Science ®Google Scholar
• ThivoletJ, BarthelemyH, Rigot-MullerG, BendelacA. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet. 1985;1(8424):334–335. doi:10.1016/S0140-6736(85)91099-2
   Web of Science ®Google Scholar
• SeguraS, IranzoP, Martinez-de PabloI, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol. 2007;56(6):960–967. doi:10.1016/j.jaad.2006.06.02917368865
   PubMed Web of Science ®Google Scholar
• RuoccoE, WolfR, RuoccoV, BrunettiG, RomanoF, Lo SchiavoA. Pemphigus: associations and management guidelines: facts and controversies. Clin Dermatol. 2013;31(4):382–390. doi:10.1016/j.clindermatol.2013.01.00523806155
   PubMed Web of Science ®Google Scholar
• SvecovaD. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects. Australas J Dermatol. 2016;57(2):141–144. doi:10.1111/ajd.1242226581165
   PubMed Web of Science ®Google Scholar
• RoujeauJC, AndreC, Joneau FabreM, et al. Plasma exchange in pemphigus. Uncontrolled study of ten patients. Arch Dermatol. 1983;119(3):215–221. doi:10.1001/archderm.1983.016502700330136824359
   PubMedGoogle Scholar
• FeldmanRJ, AhmedAR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. 2011;7(4):529–541. doi:10.1586/eci.11.2221790294
   PubMed Web of Science ®Google Scholar
• ColliouN, PicardD, CaillotF, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5(175):175ra130. doi:10.1126/scitranslmed.3005166
   Web of Science ®Google Scholar
• Biogen Inc., Inc. G. Rituxan® (Rituximab) US prescribing information [updated 01/2019]; 1997.
   Google Scholar
• CianchiniG, LupiF, MasiniC, CoronaR, PudduP, De PitaO. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67(4):617–622. doi:10.1016/j.jaad.2011.11.00722243765
   PubMed Web of Science ®Google Scholar
• LeshemYA, HodakE, DavidM, AnhaltGJ, MimouniD. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68(3):404–411. doi:10.1016/j.jaad.2012.08.01023044076
   PubMed Web of Science ®Google Scholar
• AhmedAR, SpigelmanZ, CavaciniLA, PosnerMR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772–1779. doi:10.1056/NEJMoa06293017065638
   PubMed Web of Science ®Google Scholar
• JolyP, Maho-VaillantM, Prost-SquarcioniC, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–2040. doi:10.1016/S0140-6736(17)30070-328342637
   PubMed Web of Science ®Google Scholar
• JolyP, HorwathB, PatsatsiA, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–1913. doi:10.1111/jdv.1675232830877
   PubMed Web of Science ®Google Scholar
• MurrellDF, PenaS, JolyP, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575–585 e571. doi:10.1016/j.jaad.2018.02.02129438767
   PubMed Web of Science ®Google Scholar
• ShimizuT, TakebayashiT, SatoY, et al. Grading criteria for disease severity by pemphigus disease area index. J Dermatol. 2014;41(11):969–973. doi:10.1111/1346-8138.1264925346300
   PubMed Web of Science ®Google Scholar
• RosenbachM, MurrellDF, BystrynJC, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129(10):2404–2410. doi:10.1038/jid.2009.7219357707
   PubMed Web of Science ®Google Scholar
• KimTH, ChoiY, LeeSE, LimJM, KimSC. Adjuvant rituximab treatment for pemphigus: a retrospective study of 45 patients at a single center with long-term follow up. J Dermatol. 2017;44(6):615–620. doi:10.1111/1346-8138.1375728186358
   PubMed Web of Science ®Google Scholar
• MurrellDF, DickS, AhmedAR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043–1046. doi:10.1016/j.jaad.2008.01.01218339444
   PubMed Web of Science ®Google Scholar
• VinayK, CazzanigaS, AmberKT, FeldmeyerL, NaldiL, BorradoriL. Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018;78(4):806–808. doi:10.1016/j.jaad.2017.11.02429146127
   PubMed Web of Science ®Google Scholar
• HebertV, VermeulinT, TanguyL, et al. Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial. Br J Dermatol. 2020;183(1):121–127. doi:10.1111/bjd.1856331657454
   PubMed Web of Science ®Google Scholar
• SharmaVK, GuptaV, BhariN, SinghV. Rituximab as an adjuvant therapy for pemphigus: experience in 61 patients from a single center with long-term follow-up. Int J Dermatol. 2020;59(1):76–81.
   Web of Science ®Google Scholar
• KuriharaY, YamagamiJ, FunakoshiT, et al. Rituximab therapy for refractory autoimmune bullous diseases: a multicenter, open-label, single-arm, Phase 1/2 study on 10 Japanese patients. J Dermatol. 2019;46(2):124–130. doi:10.1111/1346-8138.1473230585649
   PubMed Web of Science ®Google Scholar
• KushnerCJ, WangS, TovanabutraN, TsaiDE, WerthVP, PayneAS. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol. 2019;155(12):1404–1409. doi:10.1001/jamadermatol.2019.3236
   PubMed Web of Science ®Google Scholar
• ChenDM, OdueyungboA, CsinadyE, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182(5):1111–1119. doi:10.1111/bjd.1848231487383
   PubMed Web of Science ®Google Scholar
• DeD, BishnoiA, HandaS, MahapatraT, MahajanR. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: a retrospective single-center review of up to 68 months follow-up. Indian J Dermatol Venereol Leprol. 2020;86(1):39–44. doi:10.4103/ijdvl.IJDVL_848_1731089006
   PubMed Web of Science ®Google Scholar
• BalighiK, DaneshpazhoohM, AkbariZ, TavakolpourS, AzimiP, AzizpourA. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months. J Dermatolog Treat. 2019;30(4):346–349. doi:10.1080/09546634.2018.150904930081690
   PubMed Web of Science ®Google Scholar
• BalighiK, DaneshpazhoohM, MahmoudiH, et al. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better? Arch Dermatol Res. 2019;311(1):63–69. doi:10.1007/s00403-018-1881-130506422
   PubMed Web of Science ®Google Scholar
• LunardonL, TsaiKJ, PropertKJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031–1036. doi:10.1001/archdermatol.2012.152222710375
   PubMedGoogle Scholar
• HammersCM, ChenJ, LinC, et al. Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years. J Invest Dermatol. 2015;135(3):742–749. doi:10.1038/jid.2014.29125142730
   PubMed Web of Science ®Google Scholar
• SchmidtE. Rituximab as first-line treatment of pemphigus. Lancet. 2017;389(10083):1956–1958. doi:10.1016/S0140-6736(17)30787-028342636
   PubMed Web of Science ®Google Scholar
• SuchonwanitP, HectorCE, Bin SaifGA, McMichaelAJ. Factors affecting the severity of central centrifugal cicatricial alopecia. Int J Dermatol. 2016;55(6):e338–343. doi:10.1111/ijd.1306126769173
   PubMed Web of Science ®Google Scholar
• ChoYT, LeeFY, ChuCY, WangLF. First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. Acta Derm Venereol. 2014;94(4):472–473. doi:10.2340/00015555-174624217821
   PubMed Web of Science ®Google Scholar
• ChoYT, HuangYM, WangLF, ChuCY. Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy. J Formos Med Assoc. 2020;119(1 Pt 2):230–237. doi:10.1016/j.jfma.2019.04.02031103376
   PubMed Web of Science ®Google Scholar
• HertlM, JedlickovaH, KarpatiS, et al. Pemphigus. S2 Guideline for diagnosis and treatment–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(30):405–414. doi:10.1111/jdv.1277225338479
   PubMed Web of Science ®Google Scholar
• AmberKT, HertlM. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol. 2015;29(4):777–782. doi:10.1111/jdv.1267825185723
   PubMed Web of Science ®Google Scholar
• WangHH, LiuCW, LiYC, HuangYC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928–932. doi:10.2340/00015555-211625881672
   PubMed Web of Science ®Google Scholar
• TavakolpourS, MahmoudiH, BalighiK, AbediniR, DaneshpazhoohM. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–138. doi:10.1016/j.intimp.2017.11.00529132070
   PubMed Web of Science ®Google Scholar
• KerenZ, NaorS, NussbaumS, et al. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. Blood. 2011;117(11):3104–3112. doi:10.1182/blood-2010-09-30798321228330
   PubMed Web of Science ®Google Scholar
• HarmanKE, SeedPT, GratianMJ, BhogalBS, ChallacombeSJ, BlackMM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001;144(4):775–780. doi:10.1046/j.1365-2133.2001.04132.x11298536
   PubMed Web of Science ®Google Scholar
• EmingR, HertlM. Immunoadsorption in pemphigus. Autoimmunity. 2006;39(7):609–616. doi:10.1080/0891693060097204017101505
   PubMed Web of Science ®Google Scholar
• AbasqC, MouquetH, GilbertD, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009;145(5):529–535. doi:10.1001/archdermatol.2009.919451496
   PubMedGoogle Scholar
• AlbersLN, LiuY, BoN, SwerlickRA, FeldmanRJ. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017;77(6):1074–1082. doi:10.1016/j.jaad.2017.07.01228927663
   PubMed Web of Science ®Google Scholar
• SalehMA. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. J Am Acad Dermatol. 2018;79(1):97–103. doi:10.1016/j.jaad.2018.01.02929408700
   PubMed Web of Science ®Google Scholar
• MignardC, Maho-VaillantM, GolinskiML, et al. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a Randomized Clinical Trial. JAMA Dermatol. 2020;156(5):545–552. doi:10.1001/jamadermatol.2020.029032186656
   PubMed Web of Science ®Google Scholar
• AhmedAR, ShettyS. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015;14(4):323–331. doi:10.1016/j.autrev.2014.12.00225499920
   PubMed Web of Science ®Google Scholar
• HeelanK, Al-MohammediF, SmithMJ, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol. 2014;150(7):703–708. doi:10.1001/jamadermatol.2013.673924500264
   PubMed Web of Science ®Google Scholar
• AnandanV, JameelaWA, SowmiyaR, KumarMMS, LavanyaP. Rituximab: a magic bullet for pemphigus. J Clin Diagn Res. 2017;11(4):WC01–WC06. doi:10.7860/JCDR/2017/21868.9717
   Google Scholar